Laden…
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
Nefazodone is an antidepressant from the SARI class that acts by inhibiting serotonin reuptake and has antagonistic effects at 5-HT2A and 5-HT2C receptors. It is used to treat depression and additionally possesses anxiolytic and sedative properties. Due to potential side effects, particularly liver damage, careful medical monitoring is required.
Class
SARI (Serotonin Antagonist and Reuptake Inhibitor)
Pharmacological context
Mechanism
5-HT2A antagonist, 5-HT2C antagonist
Short read on known pharmacology
Interactions
No curated pairs visible
Curated visible combinations
Risk theme
Interpret risks carefully
Condensed from structured notes
Translation in progress
The German version has more complete content. This English page is being expanded; safety-critical risk and interaction sections may still appear while translation continues.
Receptor Targets
Mechanism of Action
Nefazodone acts through the following pharmacological mechanisms:
Designations
IUPAC: 2-[3-[4-(3-chlorophenyl)piperazino]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der Serotonintransporter (SERT/5-HTT) ist ein Natrium-abhängiger Monoamintransporter, der Serotonin aus dem synaptischen Spalt zurück in die präsynaptische Zelle transportiert. Er ist das primäre Ziel von SSRI und MDMA.
Der 5-HT2C-Rezeptor ist ein Gq/11-gekoppelter Serotoninrezeptor, der an der Regulation von Appetit, Stimmung und Angst beteiligt ist. Er wird von verschiedenen Psychedelika als sekundäres Ziel aktiviert und moduliert dopaminerge Signalwege.
Synapedia Evidence
Effects & Pharmacology translation in progress
English prose is being expanded. The German version currently has more detail.
Reported range 300–400 mg
Oral
| Tier | Dosage |
|---|---|
| Light | 100–200 mg |
| Reported | 300–400 mg |
| Strong | 600 mg |
Oral
Onset
1–2 weeks
Peak
4–6 weeks
Avoid uncertain dosage claims and do not infer numbers when data is unclear.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Schläfrigkeit, Schwindel und gastrointestinale Beschwerden.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.